CDC Endorses Doxycycline as Post-Exposure STD Prevention

On June 5, 2024, U.S. health authorities issued new guidelines recommending the antibiotic doxycycline as a post-exposure preventive measure against certain sexually transmitted diseases (STDs) for specific high-risk groups. The U.S. Centers for Disease Control and Prevention (CDC) now advises that gay and bisexual men, as well as transgender women who have had an STD in the past year and are at high risk of re-infection, consider taking doxycycline as a post-exposure prophylaxis (PEP) to reduce their risk of contracting syphilis, chlamydia, and gonorrhea.

The updated recommendations were detailed in the CDC's Morbidity and Mortality Weekly Report. CDC experts emphasized the urgency of finding more effective methods to curb the spread of STDs, particularly among high-risk populations. “There are no vaccines and few chemoprophylaxis options available for preventing bacterial STDs, which have been on the rise in the United States and disproportionately impact gay, bisexual men, and transgender women,” said Laura Bachmann, Chief Medical Officer of the CDC's Division of STD Prevention.

Evidence supporting the use of doxycycline as a preventive measure comes from three significant randomized controlled trials. These studies demonstrated that a 200-milligram dose of doxycycline, taken within 72 hours after sexual intercourse, can significantly decrease the incidence of syphilis and chlamydia by over 70% and gonorrhea by approximately 50%. Based on these findings, the CDC's new guidelines suggest that healthcare providers consider prescribing a single 200-milligram dose of doxycycline to be taken within three days of unprotected sex for those who meet the criteria.

San Francisco has been a pioneer in adopting this preventive approach. In October 2022, the San Francisco Department of Public Health began recommending doxycycline PEP for gay and bisexual men and transgender women. Subsequent research in the city, presented at a medical conference in March, indicated that just one dose of doxycycline taken post-intercourse halved the number of chlamydia and syphilis cases.

“This rapid and significant reduction in STI cases is exactly what we aim for in STI prevention,” remarked Dr. Hyman Scott, Medical Director at the San Francisco Department of Public Health, in an interview with the New York Times. The positive outcomes observed in San Francisco support the CDC's move to expand the recommendation to other high-risk groups.

While the new guidelines represent a significant step forward, CDC officials caution that doxycycline PEP is not recommended for all American adults due to insufficient evidence supporting its effectiveness in broader populations. The focus remains on those most at risk, specifically gay and bisexual men and transgender women who have had an STD in the past year.

Overall, the updated CDC guidelines reflect a proactive approach to reducing the transmission of bacterial STDs among high-risk populations in the U.S. By recommending doxycycline as a post-exposure preventive measure, health officials hope to see a substantial decrease in the incidence of these infections, ultimately contributing to better public health outcomes.